Explore all resources related to
With the ability to measure fast transitions in undiluted crude samples, all within a disposable cartridge, the Creoptix® WAVEsystem makes challenging studies possible.
Sybody® candidates compete for ACE2 binding onto SARS-CoV-2 Spike RBD
Rapid kinetic characterization for inhibition assays
Listen to Markus Seeger (University of Zurich) and Rony Nehmé (Creoptix) discuss binding affinities and selectivity of Sybody® candidates to the receptor-binding domain (RBD) region of SARS-CoV-2 Spike protein. Highlights:
- Why ELISA signals alone are not enough to predict potency in biologics development
- Why did Markus choose the WAVEsystem for the biomolecular interaction analysis at his lab?
- Why choosing the right candidates at the very early stages of research matters.
Real is relevant
SARS-CoV-2 proved challenging in ways current technologies were unable to address, limiting studies to extrapolations and inferences. It’s through innovation and technologies like the Creoptix® WAVEsystem that advance discovery and understanding. The drive to know more, study every angle, and make every measurement. With the ability to measure fast transitions in undiluted crude samples, all within a disposable cartridge, the WAVE makes challenging studies possible.
J. D. Walter, C. A. J. Hutter, A. A. Garaeva, M. Scherer, I. Zimmermann, M. Wyss, J. Rheinberger, Y. Ruedin, J. C. Earp, P. Egloff, M. Sorgenfrei, L. Hürlimann, I. Gonda, G. Meier, S. Remm, S. Thavarasah, G. Zimmer, D. J. Slotboom, C. Paulino, P. Plattet, M. A. Seeger. “Highly potent bispecific sybodies neutralize SARS-CoV-2.”
J. D. Walter, C. A. .J. Hutter, I. Zimmermann, M. Wyss, P. Egloff, M. Sorgenfrei, L. M. Hürlimann, I. Gonda, G. Meier, S. Remm, S. Thavarasah, P. Plattet, M. A. Seeger. “Sybodies targeting the SARS-CoV-2 receptor-binding domain.”
Early stage kinetics and validation of ELISA data
- High-quality kinetics in a wide range of crude samples ranging from peptides to membrane proteins and relevant clinical samples.
- WAVE goodbye to lengthy and laborious receptor purification procedures.
- Welcome contaminants and work with crude samples.
Antibody characterization from COVID-19 patient plasma binding to SARS-CoV-2 antigens
In this TechNote, we show how the WAVEsystem can be used for the characterization of binding affinity and kinetics of antibodies raised against SARSCoV-2 in clinical human blood plasma samples. With innovative disposable, no-clog microfluidics and high sensitivity, the WAVEsystem opens the door for antibody characterization directly from clinical blood plasma samples. The methods described here are also compatible with high concentrations of serum and plasma of SARS-CoV-2 patients’ samples.
Shedding light on Sybody® candidates binding onto SARS-CoV-2 spike RBD
In this TechNote we show how the WAVE system can be used to understand the binding dynamics of Sybody® candidates to the receptor binding domain (RBD) of SARS-CoV-2, both provided by Linkster Therapeutics AG and the University of Zürich. With high sensitivity and robust microfluidics, the WAVEsystem is suitable for competition assays, confirming and enriching ELISA data. By providing a rapid kinetic characterization for inhibition assays, with ACE2 kindly provided by leadXpro, the WAVE is accelerating the development of therapeutics against SARS-CoV-2.